Roundup Plaintiffs Request Delay on $7.25 Billion Bayer Settlement Approval

• The settlement was announced only 15 days before the scheduled March 4 preliminary approval hearing, which plaintiffs' lawyers argue is too fast-tracked
• Approximately 65,000 Roundup-related claims remain pending in state and federal courts that Bayer is attempting to resolve
• The legal challenge was filed in St. Louis state court and represents the first significant pushback against the German company's nationwide settlement proposal

Summary

Key Development: Law firms representing approximately 20,000 plaintiffs have requested a Missouri judge delay review of Bayer's proposed $7.25 billion nationwide settlement related to Roundup weedkiller litigation. The firms argue that a preliminary approval hearing scheduled for March 4—just 15 days after the settlement announcement—would be rushed and violate the rights of tens of thousands of cancer patients and their families.

Legal Context: This marks the first significant organized resistance to Bayer's attempt to resolve most of the remaining 65,000 Roundup claims pending in state and federal courts. The filing was submitted to a state court in St. Louis on February 25.

Background: Bayer inherited the Roundup litigation following its acquisition of Monsanto. Plaintiffs allege that exposure to the glyphosate-based herbicide caused cancer and other injuries. The German pharmaceutical and chemical giant has faced thousands of lawsuits over the product.

Market Implications: The settlement delay request introduces uncertainty into Bayer's efforts to put the costly Roundup litigation behind it. The $7.25 billion settlement represents a substantial financial commitment, and prolonged legal proceedings could impact Bayer's ability to draw a line under these liabilities. Any extension of the approval timeline may affect investor confidence and the company's financial planning, particularly as it attempts to move forward from one of its most significant legal challenges since acquiring Monsanto.

The outcome will be closely watched by shareholders and legal observers as an indicator of how complex mass tort settlements proceed.